For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...
Angiotensin II (Ang II)* is a multifunctional hormone that influences the function of cardiovascular cells through a complex series of intracellular signaling events initiated by the interaction of ...
Please provide your email address to receive an email when new articles are posted on . More inpatients had a discrepancy in eGFR compared with outpatients. Characteristics associated with a large ...
At its December meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Aumseqa (aumolertinib mesylate, SFL Pharmaceuticals ...
Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options. Dr. Girindra Raval sat down for an interview ...
Having a cystatin C-based eGFR value at least 30% lower than creatinine-based eGFR is associated with increased risks of early death, cardiovascular events, and kidney failure requiring replacement ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...
A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results